SCHEMBL1692018

SCHEMBL1692018

CCCC1(C(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2)CCNC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 16/20 0.43
SLC6A4 P31645 16/20 0.43
SLC6A3 Q01959 16/20 0.43
CYP2D6 P10635 15/20 0.43
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA13 Q8N1Q1 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
HTR6 P50406 1/20 0.35
KIF18A Q8NI77 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1692017 0.83 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL415464 0.81 CYP2D6 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL413852 0.75 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL414052 0.74 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL414811 0.73 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL414970 0.73 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL414945 0.73 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL1692094 0.72 L3MBTL1 (0.38) SLC6A2SLC6A4SLC6A3
SCHEMBL414982 0.72 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL414973 0.72 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011524396-A 2011-09-01 JP claimed
EP-2297096-A2 ARYL KETONE AS MRI F. Hoffmann-La Roche AG (CH) 2011-03-23 EP claimed
US-20090318493-A1 Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2009-12-24 US claimed
WO-2009153178-A2 ARYL KETONE AS MRI F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO claimed
EP-2297096-A2 ARYL KETONE AS MRI F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
US-20090318493-A1 Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2009-12-24 US disclosed
WO-2009153178-A2 ARYL KETONE AS MRI F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318493-A1 Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof TPH2, TPH1, ADRA2C SLC6A2 71/4885SLC6A4 57/4885SLC6A3 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.